Key result
High plasma adrenomedullin concentrations (≥3.5 Fmol/mL) following AMI were associated with significantly higher mortality (P<0.01) and lower subacute LVEF (52% vs 59%, P<0.05).
Why the study?
Does high plasma adrenomedullin concentration predict mortality and deterioration of left-ventricular systolic function in patients with acute myocardial infarction?
Cohort (n=124)
Does high plasma adrenomedullin concentration predict mortality and deterioration of left-ventricular systolic function in patients with acute myocardial infarction?
Absolute Event Rate: 52% vs 59%
p-value: p=<0.05
Plasma adrenomedullin concentration measured 24 hours after AMI onset is an independent predictor of mortality and deterioration of left-ventricular systolic function.
May refine post-AMI risk stratification; hypothesis-generating and requires prospective validation before clinical use.
The purpose of this study was to investigate the relationship between plasma adrenomedullin concentration levels and left-ventricular systolic function in patients with acute myocardial infarction (AMI), and to assess whether these findings can be used to predict clinical outcomes, including mortality. One hundred twenty-four consecutive first AMI attack subjects were successfully reperfused with primary percutaneous coronary intervention therapy. Plasma adrenomedullin concentrations were evaluated at 24 hours from onset. Left ventriculograms of all patients taken in the acute (soon after reperfusion therapy) and subacute (21 +/-9 days after onset) phases were used to evaluate left-ventricular ejection fraction (LVEF), and the difference in LVEF (delta-LVEF) between the two stages calculated. There were significantly more patients with cardiogenic shock in the H-Adm group (above the median value of plasma adrenomedullin concentrations > or =3.5 Fmol/mL) than in the L-Adm (< 3.5 Fmol/mL) group (p<0.0001). There was significantly higher mortality in the H-Adm group (p<0.01). Multivariate analysis identified plasma adrenomedullin concentrations alone as an independent predictor of mortality (p<0.05). There were no significant differences in acute-stage LVEF between the groups. LVEF in the subacute stage was, however, significantly lower in the H-Adm group than in the L-Adm group (52 +/-12% vs 59 +/-11%, p<0.05). Also, delta-LVEF was significantly lower in the H-Adm group than in the L-Adm group (1.9 +/-9.7% vs 6.3 +/-10.3%, p<0.01). Plasma adrenomedullin concentrations in the early phase of AMI correlate closely with the severity of heart failure, and may offer important prognostic information about the risk of mortality. Our data suggest that plasma adrenomedullin concentrations may be an independent predictor of the deterioration of left-ventricular systolic function.
No takes yet. Share an insight, caveat, or question.
Katayama et al. (2005) conducted a cohort in Acute myocardial infarction (n=124). High plasma adrenomedullin concentration (≥3.5 Fmol/mL) vs. Low plasma adrenomedullin concentration (<3.5 Fmol/mL) was evaluated on Left-ventricular ejection fraction (LVEF) in the subacute stage (p=<0.05). High plasma adrenomedullin concentrations (≥3.5 Fmol/mL) following AMI were associated with significantly higher mortality (P<0.01) and lower subacute LVEF (52% vs 59%, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: